<DOC>
	<DOCNO>NCT01046916</DOCNO>
	<brief_summary>This multicenter phase 2 open-label single-arm study evaluate safety efficacy TAK-700 patient castration-resistant prostate cancer ( CRPC ) without radiographic evidence metastasis rise prostate-specific antigen ( PSA ) .</brief_summary>
	<brief_title>Safety Efficacy Study TAK-700 Patients With Nonmetastatic Castration-resistant Prostate Cancer Rising Prostate-specific Antigen</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion : Male patient 18 year old Eastern Cooperative Oncology Group performance status 02 Male patient Practice effective barrier contraception study 4 month last dose study drug , OR Abstain heterosexual intercourse . Voluntary write consent Histologically cytologically confirm diagnosis prostate adenocarcinoma without radiographic evidence metastasis rise PSA follow patient 's recent antineoplastic therapy despite castrate concentration testosterone Baseline PSA must great equal 2 ng/mL PSA doubling time must less equal 8 month OR baseline PSA must great equal 8 ng/mL PSA doubling time great 8 month Has undergone orchiectomy continue receive GnRH analogue therapy Meet screen laboratory value specify protocol Patients meet follow exclusion criterion enrol study : Known hypersensitivity TAK700 related compound Received follow within 30 day prior first dose TAK700 : investigational compound ; prior herbal product know decrease PSA ; radiation therapy prostate cancer ; OR chronic therapy corticosteroid Received prior therapy aminoglutethimide ketoconazole Received antiandrogen therapy within 4 week flutamide 6 week others prior first dose study drug Received prior chemotherapy prostate cancer Current bladder neck outlet obstruction cause prostate cancer , current spinal cord compression , current bilateral hydronephrosis Symptoms investigator deems related prostate cancer Diagnosis treatment another malignancy within 2 year precede first dose study drug except nonmelanoma skin cancer situ malignancy completely resect History adrenal insufficiency Uncontrolled cardiovascular condition Known history human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C Unwilling unable comply protocol Major surgery serious infection within 14 day first dose TAK700 Lifethreatening illness unrelated cancer Uncontrolled nausea , vomit diarrhea Known gastrointestinal disease procedure could interfere oral absorption tolerance TAK700</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>